Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of YHI-1702 (duvelisib) in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
jRCT2071210133Phase 2Completed
- Sponsor
- Yakult Honsha
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in adult T-cell leukemia-lymphoma (ATLL), sponsored by Yakult Honsha. Primary endpoint: Overall response rate. Started Apr 2022; status: completed.
02
Drugs
duvelisib
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2071210133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210133.